Edmund S. Cibas BSD. Cytology: Diagnostic Principles and Clinical Correlates. 5th ed: Elsevier; 2021.

Davidov T, Trooskin SZ, Shanker BA, Yip D, Eng O, Crystal J, et al. Routine second-opinion cytopathology review of thyroid fine needle aspiration biopsies reduces diagnostic thyroidectomy. Surgery. 2010;148(6):1294–9; discussion 9–301.

Bajaj J, Morgenstern N, Sugrue C, Wasserman J, Wasserman P. Clinical impact of second opinion in thyroid fine needle aspiration cytology (FNAC): A study of 922 interinstitutional consultations. Diagn Cytopathol. 2012;40(5):422-9.

Article  PubMed  Google Scholar 

Walts AE, Bose S, Fan X, Frishberg D, Scharre K, de Peralta-Venturina M, et al. A simplified Bethesda System for reporting thyroid cytopathology using only four categories improves intra- and inter-observer diagnostic agreement and provides non-overlapping estimates of malignancy risks. Diagn Cytopathol. 2012;40 Suppl 1:E62-8.

PubMed  Google Scholar 

Olson MT, Boonyaarunnate T, Aragon Han P, Umbricht CB, Ali SZ, Zeiger MA. A tertiary center's experience with second review of 3885 thyroid cytopathology specimens. J Clin Endocrinol Metab. 2013;98(4):1450-7.

Article  PubMed  CAS  Google Scholar 

PA ASV. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes. 3rd ed ed. Switzerland: Springer; 2023.

Horne MJ, Chhieng DC, Theoharis C, Schofield K, Kowalski D, Prasad ML, et al. Thyroid follicular lesion of undetermined significance: Evaluation of the risk of malignancy using the two-tier sub-classification. Diagn Cytopathol. 2012;40(5):410-5.

Article  PubMed  Google Scholar 

Zhao H, Guo H, Zhao L, Cao J, Sun Y, Wang C, et al. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China. Cancer Cytopathol. 2021;129(8):642-8.

Article  PubMed  Google Scholar 

Bagis M, Can N, Sut N, Tastekin E, Erdogan EG, Bulbul BY, et al. A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone Between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More. Endocr Pathol. 2024;35(1):51–76.

Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol. 2012;56(4):333-9.

Article  PubMed  Google Scholar 

Sheffield BS, Masoudi H, Walker B, Wiseman SM. Preoperative diagnosis of thyroid nodules using the Bethesda System for Reporting Thyroid Cytopathology: a comprehensive review and meta-analysis. Expert Rev Endocrinol Metab. 2014;9(2):97-110.

Article  PubMed  CAS  Google Scholar 

Iskandar ME, Bonomo G, Avadhani V, Persky M, Lucido D, Wang B, et al. Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III. Surgery. 2015;157(3):510-7.

Article  PubMed  Google Scholar 

Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023-9.

Article  PubMed  PubMed Central  Google Scholar 

Ha EJ, Chung SR, Na DG, Ahn HS, Chung J, Lee JY, et al. 2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol. 2021;22(12):2094-123.

Article  PubMed  PubMed Central  Google Scholar 

Olson MT, Clark DP, Erozan YS, Ali SZ. Spectrum of risk of malignancy in subcategories of 'atypia of undetermined significance'. Acta Cytol. 2011;55(6):518-25.

Article  PubMed  Google Scholar 

VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol. 2011;136(4):572-7.

Article  PubMed  Google Scholar 

Hyeon J, Ahn S, Shin JH, Oh YL. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results. Cancer Cytopathol. 2014;122(5):368-76.

Article  PubMed  CAS  Google Scholar 

Park HJ, Moon JH, Yom CK, Kim KH, Choi JY, Choi SI, et al. Thyroid "atypia of undetermined significance" with nuclear atypia has high rates of malignancy and BRAF mutation. Cancer Cytopathol. 2014;122(7):512-20.

Article  PubMed  CAS  Google Scholar 

Luu MH, Fischer AH, Stockl TJ, Pisharodi L, Owens CL. Atypical follicular cells with equivocal features of papillary thyroid carcinoma is not a low-risk cytologic diagnosis. Acta Cytol. 2011;55(6):526-30.

Article  PubMed  Google Scholar 

Mathur A, Najafian A, Schneider EB, Zeiger MA, Olson MT. Malignancy risk and reproducibility associated with atypia of undetermined significance on thyroid cytology. Surgery. 2014;156(6):1471–6; discussion6.

Shrestha RT, Hennessey JV. Cytologic subclassification of atypia of undetermined significance may predict thyroid nodules more likely to be malignant at surgery. Diagn Cytopathol. 2016;44(6):492-8.

Article  PubMed  Google Scholar 

Gan TR, Nga ME, Lum JH, Wong WM, Tan WB, Parameswaran R, et al. Thyroid cytology-nuclear versus architectural atypia within the "Atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy. Cancer Cytopathol. 2017;125(4):245-56.

Article  PubMed  Google Scholar 

Kim SD, Han SH, Jeong WJ, Kim H, Ahn SH. Differences in Clinical Features Between Subcategories of "Atypia/Follicular Lesion of Undetermined Significance". Endocr Pathol. 2017;28(3):247-52.

Article  PubMed  Google Scholar 

Jin X, Lew M, Pantanowitz L, Smola B, Jing X. Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules. Cancer Cytopathol. 2022;130(11):891-8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Altinboga AA, Altunkaya C, Ahsen H, Gumuskaya B, Topaloglu O, Ulusoy S, et al. Diagnosing atypia of undetermined significance in thyroid fine needle aspiration samples using nuclear scoring. Ann Diagn Pathol. 2019;41:112-5.

Article  PubMed  Google Scholar 

Guleria P, Agarwal S, Iyer VK, Jain D, Mathur SR, Yadav D. Subcategorisation of AUS/FLUS thyroid lesions as per the 2017 Bethesda System for Reporting Thyroid Cytopathology: a retrospective study from a tertiary care centre analysing risk of malignancy (ROM) of the different subcategories. J Clin Pathol. 2019;72(11):771-7.

Article  PubMed  CAS  Google Scholar 

Kaymaz E, Gun BD, Tasdoven I, Kokturk F. Is Subdivision of Atypia of Undetermined Significance AUS/Follicular Lesion of Undetermined Significance Cases According to Detailed Nuclear Features Vital for Assessing the Risk of Malignancy? J Cytol. 2020;37(4):204-9.

Article  PubMed  PubMed Central  Google Scholar 

Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45(5):818-21.

Article  PubMed  CAS  Google Scholar 

Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005;63(5):588-93.

Article  PubMed  CAS  Google Scholar 

Lee SE, Hwang TS, Choi YL, Kim WY, Han HS, Lim SD, et al. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF(V600E) Mutation. Thyroid. 2017;27(6):802-10.

Article  PubMed  CAS  Google Scholar